Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATH Study: Benralizumab and Airway Remodeling in Severe Asthma
2018-002498-23Phase 3Active
- Sponsor
- Policlinico Paolo Giaccone
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of benralizumab in severe asthma and eosinophilic asthma (EA), sponsored by Policlinico Paolo Giaccone. Primary endpoints: Reduction in number of exacerbations and symptoms of severe asthma and Change in HRCT markers of airway remodeling. Started May 2021; status: active.
02
Drugs
benralizumab
03
Conditions
severe asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2018-002498-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002498-23.